Zhitong Financial App News, Sino Biopharmaceutical (01177) issued an announcement that during the six-month period ended June 30, 2022, due to the lower financial performance of an associated company than in the same period last year, the profit attributable to the group belonging to the parent company decreased by about 78% to about 1.871 billion yuan compared with the same period last year. During the period, the profit of the attributable associate decreased, but the performance of the group's main business was in line with expectations, and the performance grew steadily compared with the same period last year.